Sagent Pharmaceuticals Company Profile (NASDAQ:SGNT)

About Sagent Pharmaceuticals (NASDAQ:SGNT)

Sagent Pharmaceuticals logoSagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company's operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:SGNT
  • CUSIP: 78669210
  • Web:
Average Prices:
  • 50 Day Moving Avg: $21.72
  • 200 Day Moving Avg: $15.37
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 29.77
  • P/E Growth: 0.00
  • Net Margins: -0.72%
  • Return on Equity: -0.81%
  • Return on Assets: -0.59%
  • Beta: 1.66

Frequently Asked Questions for Sagent Pharmaceuticals (NASDAQ:SGNT)

What is Sagent Pharmaceuticals' stock symbol?

Sagent Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGNT."

How were Sagent Pharmaceuticals' earnings last quarter?

Sagent Pharmaceuticals Inc (NASDAQ:SGNT) announced its quarterly earnings results on Tuesday, May, 3rd. The company reported ($0.15) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.01 by $0.16. The firm had revenue of $67.30 million for the quarter, compared to analysts' expectations of $74.30 million. Sagent Pharmaceuticals had a negative net margin of 0.72% and a negative return on equity of 0.81%. The company's quarterly revenue was down 17.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.04 EPS. View Sagent Pharmaceuticals' Earnings History.

Who are some of Sagent Pharmaceuticals' key competitors?

How do I buy Sagent Pharmaceuticals stock?

Shares of Sagent Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sagent Pharmaceuticals' stock price today?

One share of Sagent Pharmaceuticals stock can currently be purchased for approximately $21.73.

MarketBeat Community Rating for Sagent Pharmaceuticals (NASDAQ SGNT)
Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  137 (Vote Outperform)
Underperform Votes:  198 (Vote Underperform)
Total Votes:  335
MarketBeat's community ratings are surveys of what our community members think about Sagent Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sagent Pharmaceuticals (NASDAQ:SGNT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Sagent Pharmaceuticals (NASDAQ:SGNT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/11/2016Deutsche Bank AGDowngradeBuy -> HoldN/AView Rating Details
7/12/2016Raymond James Financial, Inc.DowngradeBuy -> Market PerformN/AView Rating Details
7/11/2016Royal Bank Of CanadaDowngradeOutperform -> HoldN/AView Rating Details
7/11/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$22.00 -> $21.75N/AView Rating Details
6/17/2016Jefferies Group LLCReiterated RatingHold$13.00 -> $15.00N/AView Rating Details
6/1/2016J P Morgan Chase & CoReiterated RatingNeutralN/AView Rating Details
5/9/2016Bank of America CorporationReiterated RatingHold$13.00N/AView Rating Details
(Data available from 9/24/2015 forward)


Earnings History for Sagent Pharmaceuticals (NASDAQ:SGNT)
Earnings by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)
Earnings History by Quarter for Sagent Pharmaceuticals (NASDAQ SGNT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2016Q1$0.01($0.15)$74.30 million$67.30 millionViewN/AView Earnings Details
2/16/2016Q415($0.02)($0.55)$78.13 million$83.10 millionViewListenView Earnings Details
11/3/2015Q315($0.07)$0.01$73.84 million$75.20 millionViewN/AView Earnings Details
8/4/2015Q215$0.05($0.01)$83.28 million$77.30 millionViewN/AView Earnings Details
5/5/2015Q115$0.04$0.04$80.63 million$82.60 millionViewN/AView Earnings Details
2/19/2015Q414$0.01$0.91$76.20 million$84.40 millionViewN/AView Earnings Details
11/4/2014Q314($0.04)$0.08$64.01 million$65.40 millionViewN/AView Earnings Details
7/30/2014Q214($0.01)$0.09$67.14 million$69.20 millionViewListenView Earnings Details
5/6/2014Q114($0.02)$0.16$65.66 million$70.90 millionViewListenView Earnings Details
2/11/2014Q4($0.01)$0.11$60.25 million$64.10 millionViewListenView Earnings Details
11/5/2013($0.03)$0.10ViewN/AView Earnings Details
8/6/2013Q2 2013$0.46$59.27 million$59.60 millionViewN/AView Earnings Details
5/6/2013Q1 2013($0.03)$0.34$55.31 million$60.20 millionViewN/AView Earnings Details
11/8/2012Q312($0.20)($0.13)$48.60 million$49.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sagent Pharmaceuticals (NASDAQ:SGNT)
Current Year EPS Consensus Estimate: $0.24 EPS
Next Year EPS Consensus Estimate: $0.73 EPS


Dividend History for Sagent Pharmaceuticals (NASDAQ:SGNT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Sagent Pharmaceuticals (NASDAQ:SGNT)
Insider Trades by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)
Institutional Ownership by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)
Insider Trades by Quarter for Sagent Pharmaceuticals (NASDAQ:SGNT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/21/2016Ventures Fund V L.P. VivoMajor ShareholderSell2,005$13.55$27,167.75View SEC Filing  
11/4/2015Ventures Fund V L.P. VivoMajor ShareholderSell603,177$15.72$9,481,942.44View SEC Filing  
11/3/2015Vivo Ventures Vi, LlcMajor ShareholderSell67,283$16.32$1,098,058.56View SEC Filing  
11/2/2015Vivo Ventures Vi, LlcMajor ShareholderSell93,523$16.87$1,577,733.01View SEC Filing  
1/27/2015Morgan Stanley Investment ManaMajor ShareholderSell78,041$26.16$2,041,552.56View SEC Filing  
1/23/2015Morgan Stanley Investment ManaMajor ShareholderSell211,883$25.61$5,426,323.63View SEC Filing  
1/21/2015Morgan Stanley Investment ManaMajor ShareholderSell69,316$25.23$1,748,842.68View SEC Filing  
1/16/2015Morgan Stanley Investment ManaMajor ShareholderSell125,000$25.16$3,145,000.00View SEC Filing  
1/14/2015Morgan Stanley Investment ManaMajor ShareholderSell100,000$25.51$2,551,000.00View SEC Filing  
10/8/2014Robert J FlanaganDirectorSell16,000$31.56$504,960.00View SEC Filing  
10/7/2014Robert J FlanaganDirectorSell8,000$31.15$249,200.00View SEC Filing  
9/25/2014Robert J FlanaganDirectorSell16,000$30.01$480,160.00View SEC Filing  
9/24/2014Robert J FlanaganDirectorSell8,000$30.30$242,400.00View SEC Filing  
9/12/2014Robert J FlanaganDirectorSell16,000$28.30$452,800.00View SEC Filing  
9/11/2014Robert J FlanaganDirectorSell8,000$28.35$226,800.00View SEC Filing  
8/28/2014Robert J FlanaganDirectorSell16,000$27.19$435,040.00View SEC Filing  
8/27/2014Robert J FlanaganDirectorSell8,000$27.30$218,400.00View SEC Filing  
8/12/2014Robert J FlanaganDirectorSell16,000$24.39$390,240.00View SEC Filing  
7/31/2014Robert J FlanaganDirectorSell16,000$25.60$409,600.00View SEC Filing  
7/18/2014Robert J FlanaganDirectorSell16,000$26.18$418,880.00View SEC Filing  
7/2/2014Robert J FlanaganDirectorSell16,000$26.51$424,160.00View SEC Filing  
6/18/2014Robert J FlanaganDirectorSell16,000$23.37$373,920.00View SEC Filing  
6/4/2014Robert J FlanaganDirectorSell16,000$22.17$354,720.00View SEC Filing  
5/22/2014Robert FlanaganDirectorSell8,000$22.02$176,160.00View SEC Filing  
2/27/2014Michael LogerfoInsiderSell2,021$21.43$43,310.03View SEC Filing  
10/3/2013Morgan Stanley Investment Manamajor shareholderSell47,826$20.27$969,433.02View SEC Filing  
9/26/2013Morgan Stanley Investment Manamajor shareholderSell67,965$20.37$1,384,447.05View SEC Filing  
9/25/2013Morgan Stanley Investment Manamajor shareholderSell48,124$21.30$1,025,041.20View SEC Filing  
9/23/2013Morgan Stanley Investment Manamajor shareholderSell119,557$21.83$2,609,929.31View SEC Filing  
9/19/2013Morgan Stanley Investment Manamajor shareholderSell88,885$22.53$2,002,579.05View SEC Filing  
9/16/2013Frank KungDirectorSell1,161,717$21.25$24,686,486.25View SEC Filing  
9/16/2013Jeffrey YordonCEOSell85,813$20.03$1,718,834.39View SEC Filing  
9/16/2013Vivo Ventures Vi, Llcmajor shareholderSell622,700$21.25$13,232,375.00View SEC Filing  
8/12/2013Lorin DrakeVPSell1,000$23.69$23,690.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Sagent Pharmaceuticals (NASDAQ:SGNT)
Latest Headlines for Sagent Pharmaceuticals (NASDAQ:SGNT)
DateHeadline logoNWQ Bought 12 New Holdings in 2nd Quarter - September 16 at 7:00 PM logoForm 4 Sagent Pharmaceuticals, For: Aug 29 Filed by: Krizman Anthony - September 1 at 7:13 PM logoNichi-Iko Pharmaceutical Co., Ltd. - August 30 at 10:37 AM logoNichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the Outstanding Shares of Common Stock of Sagent Pharmaceuticals, Inc. - August 29 at 7:14 PM logoSAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delist - August 29 at 7:14 PM logoSAGENT PHARMACEUTICALS, INC. Financials - August 16 at 7:30 PM logoGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sagent Pharmaceuticals, Inc. (SGNT) - August 10 at 7:54 PM logoForm SC TO-T/A Sagent Pharmaceuticals, Filed by: Shepard Vision, Inc. - August 9 at 7:41 PM logoNichi-Iko Pharmaceutical Co., Ltd. Announces Expiration of HSR Waiting Period for Proposed Acquisition of Sagent Pharmaceuticals, Inc. - August 9 at 10:37 AM logoSAGENT PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report - August 5 at 7:38 PM logoShepard Vision, Inc., a Wholly-Owned Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd, Commences All-Cash … - August 1 at 1:01 PM logoINVESTOR ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Sagent Pharmaceuticals, Inc. Concerning the Sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd. - July 22 at 11:48 AM



Sagent Pharmaceuticals (SGNT) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by Staff